Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13

Cabaletta Bio

Cabaletta Bio

CABA

0.00

Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ: CABA) with a Overweight and lowers the price target from $14 to $13.